Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-12-01T02:46:48.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Recommended Precautions for Patients Undergoing Hemodialysis Who Have AIDS or Non-A, Non-B Hepatitis

Published online by Cambridge University Press:  02 January 2015

Martin S. Favero
Martin S. Favero*
Affiliation:
Hospital Infections Program, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia
*
Nosocomial Infections Laboratory Branch, Hospital Infections Program, Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Precautions used for dialysis patients who have acquired immunodeficiency syndrome or non-A, non-B hepatitis are based on infection control strategies developed for the control of hepatitis B in dialysis centers. Specificially, these recommendations include identifying infected patients; isolating (except for non-A, non-B hepatitis patients) patients, and separating staff, and equipment; applying blood precautions and aseptic techniques; and using good environmental control procedures. AIDS patients can be safely dialyzed by either hemodialysis or peritoneal dialysis in hospital-based or free-standing centers, or at home without risk of AIDS transmission to other patients or to staff members, if precautions that have been developed for the control of hepatitis B infection in dialysis units are employed. Further, the type of dialysis treatment, or modality, should be based on the needs of the patient and not on a fear of risk of disease transmission.

Type
Editorial Comment
Information
Infection Control & Hospital Epidemiology , Volume 6 , Issue 8 , August 1985 , pp. 301 - 305
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1985

References

1.Snydman, D, Bryan, J, Hanson, B: Hemodialysis-associated hepatitis in the United States—1972 J Infect Dis 1975; 132:109–113.Google Scholar
2.Szmuness, W, Prince, AM, Grady, GF, et al: Hepatitis B infection. A point prevalence study in 15 U.S. hemodialysis centers. JAMA 1974; 227:901–906.CrossRefGoogle ScholarPubMed
3.Alter, MJ, Favero, MS, Petersen, NJ, et al: National surveillance of dialysis-associated hepatitis and other diseases. Dialysis Transplant 1983b; 12:860–868.Google Scholar
4.Favero, MS: Dialysis-associated diseases and their control, in, Bennett, JV, Brachman, PS (eds): Hospital Infections, ed 2. Boston, Massachusetts, Little, Brown and Company Inc., 1985.Google Scholar
5.Prevention of acquired immune deficiency syndrome (AIDS): Report of interagency recommendations. MMWR 1983; 32:101–103.Google Scholar
6.Acquired immune deficiency syndrome (AIDS): Precautions for clinical and laboratory staffs. MMWR 1982; 31:577–580.Google Scholar
7.Quinn, TC: Precautions for patients hospitalized with acquired immunodeficiency syndrome. Infect Control 1983; 4:79–80.CrossRefGoogle ScholarPubMed
8. Hepatitis—Control measures for hepatitis B in dialysis centers. Viral Hepatitis: Investigation and Control Series - November 1977, HEW Publication No. (CDC) 78-8358.Google Scholar
9.Update: Prospective evaluation of health-care workers exposed via the parenteral or mucous-membrane route to blood or body fluids from patients with acquired immunodeficiency syndrome—United States. MMWR 1985; 34:101–103.Google Scholar
10.McCray, E, Winslow, N, Solomon, S, et al: Prospective evaluation of health-care workers with parenteral or mucous-membrane exposure to blood from patients with acquired immunodeficiency syndrome, United States: An Update. Presented at the International Conference on Acquired Immunodeficiency Syndrome (AIDS) April 16, 1985, Atlanta, Georgia. Centers for Disease Control, Atlanta. Abstract - p 45.Google Scholar
11.Seeff, LB, Wright, EC, Zimmerman, HI, et al: Type B hepatitis after needle-stick exposure: Prevention with hepatitis immune globulin. Ann Intern Med 1978; 88:285–293.Google Scholar
12.Rao, TKS, Manis, T, Friedman, EA: Dismal prognosis despite maintenance hemodialysis in AIDS nephropathy and chronic uremia. Abstracts of the American Society for Artificial Internal Organs, Inc. May 9, 1985, Atlanta, Georgia. American Society for Artificial Internal Organs, Boca Raton, Florida. Abstract p 47.Google Scholar
13.Favero, MS: Sterilization, disinfection, and antisepsis in the hospital, in, Manual of Clinical Microbiology, ed 4, American Society for Microbiology, Washington, DC, 1985; 952–959.Google Scholar
14.McDougal, SJ, Cort, SP, Kennedy, MS, et al: Immunoassay for the detection of infectious human retrovirus, lymphadenopathy-associated virus (LAV) J Immunol Methods 1985; 76:171–183.CrossRefGoogle ScholarPubMed
15.Martin, LS, McDougal, JS, LoskoskiSL, : Disinfection and inactivation of human T Lymphotropic Virus Type III/Lymphadenopathy Virus. J Infect Dis 1985; to be published.Google Scholar
16.Spire, B, Barre-Sinoussi, F, Montagnier, L, et al: Inactivation of Lyniphadenopathy associated virus by chemical disinfectants. Lancet October 20, 1984;899–901.Google Scholar
17.Spire, B, Dormont, D, Barre-Sinoussi, F, et al: Inactivation of Lymphadenopathy-Associated Virus by heat, gamma rays, and ultraviolet light. Lancet January 26, 1985;188–189.Google Scholar
18.Tabor, E, April, M, Seef, LB, et al: Acquired immunity to human non-A, non-B hepatitis: Cross-challenge of chimpanzees with three infectious human sera. J Infect Dis 1979; 140(5):789–793.CrossRefGoogle ScholarPubMed
19.Hollinger, FB, Mosley, JW, Szmuness, W, et al: Transfusion-transmitted viruses study: Experimental evidence for two non-A, non-B hepatitis agents. J Infect Dis 1980; 142(3):400–407.CrossRefGoogle ScholarPubMed
20.Bradley, DW, Maynard, JE, Popper, H, et al: Postransfusion non-A, non-B hepatitis: Physicochemical properties of two distinct agents. J Infect Dis 1983; 148(2):254–265.Google Scholar
21.Calbraith, RM, Dienstag, JL, Purcell, RH, et al: Non-A, non-B hepatitis associated with chronic liver disease in a hemodialysis unit. Lancet 1979; 951–953.Google Scholar
22.Bradley, DW: Transmission, etiology, and pathogenesis of viral hepatitis non-A, non-B in non-human primates, in, Chisari, FV (ed): Advances in Hepatitis Research. New York, Masson Publishing USA Inc. 1984, pp 268–280.Google Scholar
23.Alter, HJ, Purcell, RH, Holland, PV. et al: Transmissible agent in non-A, non-B hepatitis. Lancet 1978; 459–463.Google Scholar
24.Tabor, E, Gerety, RJ, Drucker, JA, et al: Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978; 463–465.Google Scholar
25.Tabor, E, Seef, Lb, Gerety, RJ: Chronic non-A, non-B hepatitis carrier state—transmissible agent documented in one patient over a six-year period. N Enql J Med 1980; 303:140–143.Google Scholar
26.Alter, MJ, Ahtone, J, Maynard, JE: Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med 1983; 99(3):330–333.Google Scholar